Literature DB >> 11120929

Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae.

N M Rothstein1, T C Quinn, G Madico, C A Gaydos, C J Lowenstein.   

Abstract

Chlamydia pneumoniae infection can exacerbate atherosclerosis in animals. To test the hypothesis that antibiotic therapy inhibits the atherogenic effects of C. pneumoniae infection, 10-week-old apolipoprotein E (ApoE) null mice were infected with C. pneumoniae or placebo, were treated for 2 weeks after infection with azithromycin or placebo, and were killed at 20 weeks of age. Infection did not affect the size of the aortic lesion, and antibiotic treatment had no effect. Another group of mice, 12-week-old ApoE mice, were infected with C. pneumoniae or placebo, were treated for 2 weeks after infection with azithromycin or placebo, and were killed at 26 weeks of age. C. pneumoniae infection increased the size of the lesion in infected mice, but azithromycin did not reduce the size of the aortic lesion in infected mice. Therefore, immediate therapy of acute infection may be necessary to prevent the proatherogenic effects of C. pneumoniae infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120929     DOI: 10.1086/317941

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 2.  Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember?

Authors:  Kensuke Shima; Gregor Kuhlenbäumer; Jan Rupp
Journal:  Med Microbiol Immunol       Date:  2010-05-06       Impact factor: 3.402

3.  Chlamydia pneumoniae infected macrophages exhibit enhanced plasma membrane fluidity and show increased adherence to endothelial cells.

Authors:  Anthony A Azenabor; Godwin Job; Olanrewaju O Adedokun
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 4.  Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Authors:  J Thomas Grayston; Robert J Belland; Gerald I Byrne; Cho Chou Kuo; Julius Schachter; Walter E Stamm; Guangming Zhong
Journal:  Pathog Dis       Date:  2014-12-04       Impact factor: 3.166

Review 5.  Infection and Atherosclerosis Development.

Authors:  Lee Ann Campbell; Michael E Rosenfeld
Journal:  Arch Med Res       Date:  2015-05-21       Impact factor: 2.235

Review 6.  Chronic infections and atherosclerosis/thrombosis.

Authors:  Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

7.  Shear Stress Enhances Chemokine Secretion from Chlamydia pneumoniae-infected Monocytes.

Authors:  Shankar J Evani; Shatha F Dallo; Ashlesh K Murthy; Anand K Ramasubramanian
Journal:  Cell Mol Bioeng       Date:  2013-09-01       Impact factor: 2.321

8.  Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial.

Authors:  Hans F Berg; Boulos Maraha; Anneke van der Zee; Siska K Gielis; Paul J M Roholl; Gert-Jan Scheffer; Marcel F Peeters; Jan A J W Kluytmans
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Elicitation of reactive oxygen species in Chlamydia pneumoniae-stimulated macrophages: a Ca2+-dependent process involving simultaneous activation of NADPH oxidase and cytochrome oxidase genes.

Authors:  Anthony A Azenabor; Shoua Yang; Godwin Job; Olanrewaju O Adedokun
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.